Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.

doi:10.1684/ejd.2020.3848

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.

European journal of dermatology : EJD - 1 Aug 2020

Dalle Stephane, Varey Emilie, Nguyen Jean-Michel, Dupuy Alain, Montaudie Henri, Lesage Candice, Mortier Laurent, Leccia Marie-Thérèse, Skowron François, Celerier Philippe, Meyer Nicolas, Dutriaux Caroline, Dalac-Rat Sophie, Khammari Amir, Lebbe Céleste, Dréno Brigitte

Abstract excerpt

BACKGROUND: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma. OBJECTIVES: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies. MATERIALS AND METHODS: A subgroup data analysis. RESULTS: Data from 1,835 patients were analysed (15.58% Stage IIIA, 39.24%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Databases, Factual

Share to France

Share to Immune Checkpoint Inhibitors

Share to Interferon-alpha

Share to Lymph Node Excision

Share to Melanoma, Cutaneous Malignant

Source

Open in PubMed

Identifiers

PMID: 32815816
DOI: 10.1684/ejd.2020.3848

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.PMID 32815816Read ↗

French updated recommendations in Stage I to III melanoma treatment and management.Semantic proximity Read ↗

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.Semantic proximity Read ↗

Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?Semantic proximity Read ↗

BRAF Mutation Correlates with Worse Local-regional Control Following Radiation Therapy in Patients with Stage III MelanomaSemantic proximity Read ↗

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity Read ↗

Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.Semantic proximity Read ↗

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.Semantic proximity Read ↗

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.Semantic proximity Read ↗

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.Semantic proximity Read ↗

Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.Semantic proximity Read ↗

A nomogram for predicting survival in patients with upper limb melanoma: A study based on the Surveillance, Epidemiology, and End Results databaseSemantic proximity Read ↗

Consensus-Derived Risk Stratification to Guide Surveillance in Primary Uveal Melanoma: The PRIME Delphi StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.